Marshall Wace’s Atossa Therapeutics ATOS Stock Holding History

Marshall Wace’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,871	Closed	-$16.6K	–	3181
2025 Q4	$16.6K	Sell	1,871 -3,801	-67%	-$48.1K	﹤0.01%	2832
2025 Q3	$74K	Buy	5,672 +4,779	+535%	+$59K	﹤0.01%	2693
2025 Q2	$11.1K	Buy	+893	New	+$10.7K	﹤0.01%	2630

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace's ATOS Position: Q1 2026 in Review

Marshall Wace sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,871 shares — an estimated $16.6K sold.

Marshall Wace first reported a position in ATOS in Q2 2025 and held it in 3 quarters. The position peaked at $74K in Q3 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Marshall Wace reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 1,871 Atossa Therapeutics shares in Q1 2026, an estimated $16.6K.
Marshall Wace first reported a position in Atossa Therapeutics in Q2 2025 and held it in 3 quarters.
Marshall Wace's Atossa Therapeutics position peaked at $74K in Q3 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.